Metabolic therapeutics in angina pectoris: History revisited with perhexiline
Received 10 November 2004; received in revised form 24 August 2005; accepted 2 January 2006. published online 08 February 2006.
Abstract
The ever-increasing burden of ischaemic heart disease and its common manifestation chronic angina pectoris calls for the exploration of other treatment options for those patients who despite the maximum conventional pharmacological and surgical interventions continue to suffer. Such exploration has led to the increasing use of new metabolically acting antianginal agents and the re-emergence of an old and somewhat forgotten pharmacological agent, perhexiline maleate. This review aims to update the cardiac nurse with knowledge to manage the care a patient receiving perhexiline maleate treatment and provide a brief review of three new metabolic agents: trimetazidine, ranolazine and etomoxir.
aFaculty of Health Sciences, University of Queensland, Australia
bDivision of Health Sciences, University of South Australia and Faculty of Health Science, University of Queensland, Australia
Corresponding author. Cardiovascular Nursing, Division of Health Sciences, Centenary Building, City East Campus, University of South Australia, Frome Road, Adelaide 5000, Australia. Tel.: +61 8 8302 1115; fax: +61 8 8302 1806.
ABSTRACT